Advances in neuropharmacology: Innovative drug strategies targeting synaptic plasticity, neuroinflammation, and ion channel regulation for future CNS treatments.

As our understanding of the molecular and cellular mechanisms underlying central nervous system (CNS) disorders expands, neuropharmacology is undergoing a paradigm shift. Despite the increasing burden of neurodegenerative and neuropsychiatric diseases, challenges such as blood-brain barrier (BBB) impermeability, drug resistance, and complex pathophysiology continue to limit effective therapeutic development. This review highlights key emerging targets, including ion channel regulation, neuroinflammation, and synaptic plasticity, as important entry points for next-generation neurotherapeutics. Advances in nanotechnology and non-invasive delivery strategies are discussed for their potential to enhance brain-targeted drug delivery and address pharmacokinetic limitations. In addition, modulation of glial networks, neurotransmitter systems, and epigenetic regulators is explored as a promising therapeutic approach. Computational tools, including artificial intelligence (AI), machine learning, and in silico modelling, are increasingly used to improve target identification and support personalised treatment strategies. Furthermore, pharmacogenomics and biomarker-based approaches enable more precise and effective treatments across diverse patient populations. Emerging interventions, such as gene-modifying therapies and nanoformulated drugs, show promise for clinical application; however, challenges related to safety, scalability, and validation remain. Overall, the integration of advanced delivery systems, computational approaches, and precision medicine is driving a shift towards mechanism-based and individualised therapies, with the potential to improve outcomes in complex CNS disorders. These challenges underscore the need for advanced drug delivery strategies capable of improving brain targeting and therapeutic efficacy in CNS disorders.